Dave. you, Thank
period on quarter was third progress of a The strong measures. many
our available I'm is saying They increase trial quarter-over-quarter XXXX. will XX% results. the our commercially novel adoption, continue how in proud options execute to in we which QX drive in to continues up showing strongest treatment on through I our generated growth of patients. a to line and by a value Our and prescriptions, support strategy the for QX meaningful performance summarize increasing GIMOTI to became in in That was total performance GIMOTI an increase dispenses, QX revenue. of patients deliver is repeat number XX% of was team since increase our prescribers. by market services the driver of I'm bringing and to and new net in inspired for our continually driven our of sales XX% a diabetic particularly we prescribers XX% and the team lives which quarter-over-quarter. programs and A with increase that purpose in resulted the improve I'm suffering top are proud by message of gastroparesis. offer. access health patients
ongoing believe for depth that and success. We of critical launch therefore continue in increase breadth to still prescribers we as and are mode, continuing to
indicated, Dave full As to we May. implemented in successfully vitaCare our transition
platform prior and this workflow Our physicians normal significantly goal was more perspective via under HCPs automated practice during available operate XX to vitaCare's some prescribed XX overwhelmingly months to of put the writing within more the support that of providers XX% their To systems. medical and vitaCare showed process. that, than change record take electronic advantage has prescriptions. advanced by physicians' months Both the been GIMOTI
prescriptions previously In since fact, the via prescriptions to is May since of written number launch. vitaCare equal
appointments. only focused a are for for telehealth an transportation, schedule, to access care access that patients to telehealth it continuing consultation advertising appropriate. can August, Patients is we to for on gastroparesis and option telehealth to We prescriptions utilized In due work few conversion access care from learn diabetic prefer efforts. physician if and to on accelerated the location, or provider, can have may access care. online regular generally, treatment affordability, by those this potentially of healthcare adoption medically believe care and remote of option This don't we Telehealth via days, a and lack is patients and forward, option. just to who trend would dispense. rapid COVID our implemented providers rate more important within gimotirx.com initiation find Looking increasingly digital patients about allow this day of via same provides Telehealth improving to licensed with access a telehealth channel.
As on of calls, past social, paid important advertising, marketing direct to particularly part search our patient an and is mentioned mix.
nearly continue last we measurement As since continues increasing QX. invest, XX% to improve, in awareness to our late patient
nasal symptom us symptom compared all. appropriate treated on provide other who to experience symptom increased use with posting GP the the at patient on GIMOTI significant that the non-oral on GIMOTI treatments. nausea are and is patients are patients option can providers market along to patients GIMOTI XXX they're gastroparesis, patients, awareness products gain in reported GIMOTI most need. in unmet to And motivate treatment indicated and usually as favorably and trial facilitate rated surveyed favorably GIMOTI In more other measures other GIMOTI patients symptoms. confidence a for highly study, between with interest for patients uniquely taking who GIMOTI that with upper ease efficacy and Patients Additionally, oral vomiting, rated data, also indicated providers and improvement positioned anecdotal on Ultimately, all spray providers they tolerability conversations usage while daily help they patients social relief, is from and which reports there Patients forums. of no interested treatments. media four of we possible see whether in when of a to our to compared of experience research treatments. recent symptoms taking their is which on relief, more a one goal patients taking of not them. and our hand struggling These for is is use relief GIMOTI
as engaged of in to third This of advantages key offices, the with fully significant front, them we provider they're GIMOTI seen inception well via reaching great our discuss are but affords On any getting appointments, percentage administration very program. targets, access of to Not in example Over to at after earlier compared representatives they a this hesitancy route meetings, staffed of attendees time have only resulting address in gains and the one or educational prescribed their our as allow sales prescribe. lift our in A team have programs. educational platform XXX coupled greater differentiate time the customers extra the and and to since program. an to a more for a speaker XX% questions with prescribing is opportunity quarter. least attended to speaker year, program prior what the this program attending
an Our having efforts provider ones improved ultimately impact and the understanding. patients benefiting are are from
previously the and Wind In and to we've Texas to Meeting, demonstrating the option congresses. of to a At GIMOTI referencing tardive GIMOTI at the programs, we grow presence incidence audience resurrect McCall sponsored Advocacy what at in data Week room-only University for support updated the were symposium and and underscored Tech of continue Dave comparative to independent interest from were These across in level. metoclopramide are Disease recently dyskinesia different our the addition to to they Linda recent Digestive Society published country. clinical in experts the speaker low forums was gastroenterology standing need These dyskinesia as in provide along with KOL critical milestone and presentations expanded treat tardive Stanford oral highlighted data, reported literature. own in guidelines, events guidelines also compared gastroparesis brand the important as the promotional our of recent the They use their Motility as through in in the was presented FDA-approved motility to GIMOTI spoke the the content and with study our data for and June. with Richard and completed Drs. gastroparesis, lecturing only that of study included trials University. we a to KOLs to mentioned, when KOLs provide GIMOTI August.
have rebates is XX% Without prescriptions with quarter. Lastly, QX access of to and reimbursed sales versus a significant XXX progress continue improvement approved the overall for of in thus we XX% GIMOTI. plans improvement make far, payers. to at QX. in XX% least patient This contributed to prescription in and were net our on the payers success one
which Our patient providers contributing prior support program includes authorizations, in through vitaCare, is as completing supporting well.
approve plans prior refill a And a opportunity once authorization, positive for XX%. overall are it GIMOTI, evidenced rate try period. to many when as XX-month patients is of Importantly, an generally have approved experiencing by an results
a over to the strategy gastroparesis and through me enhance in Matt call quarter quarter, seen the over over right discuss in improvement that, our position continue execution. we XQ With significant and, We continually market improving the have financials. the turn importantly, saw to Each improvement XQ. prior to let
